References of "DEROISY, Rita"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailReproducibility of joint space width assessment when external calibration on the radiograph is missing
DEROISY, Rita ULg; Reginster, Jean-Yves ULg; Bruyère, Olivier ULg

in Osteoporosis International (2013, April), 24(Suppl.1), 379

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailSevere prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study
Bruyère, Olivier ULg; Roux, Christian; Nicolet, Delphine ULg et al

in Annals of the Rheumatic Diseases (2012, June), 71(Suppl.3), 588

Detailed reference viewed: 14 (5 ULg)
Full Text
Peer Reviewed
See detailSeverity of incident vertebral fracture and future fracture risk: a 3-year prospective study
Bruyère, Olivier ULg; Roux, Christian; Nicolet, Delphine ULg et al

in Annals of the Rheumatic Diseases (2012, June), 71(Suppl.3), 716

Detailed reference viewed: 24 (5 ULg)
Full Text
Peer Reviewed
See detailSeverity of incident vertebral fracture and future fracture risk: a 3-year prospective study
Bruyère, Olivier ULg; Roux, Christian; Nicolet, Delphine ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 60-61

Detailed reference viewed: 27 (9 ULg)
Full Text
Peer Reviewed
See detailSevere prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study
Bruyère, Olivier ULg; Roux, Christian; Nicolet, Delphine ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 361-362

Detailed reference viewed: 13 (4 ULg)
Full Text
Peer Reviewed
See detailAssessment of joint space narrowing in knee osteoarthritis has good long-term intercentre reproducibility when read in pairs with a semi-automated device
Gensburger, Deborah; DEROISY, Rita ULg; Arlot, Monique et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 247-248

Detailed reference viewed: 19 (6 ULg)
Full Text
Peer Reviewed
See detailLong-term (3 years) reproducibility for the radiological assessment of knee osteoarthritis
DEROISY, Rita ULg; Bruyère, Olivier ULg; Gensburger, Deborah et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 219-220

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailStable precision over time when assessing the cartilage loss on knee osteoarthritis radiograph
DEROISY, Rita ULg; Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Osteoporosis International (2011, March), 22(Suppl.1), 42-43246

Detailed reference viewed: 14 (5 ULg)
Full Text
Peer Reviewed
See detailLong term agreement between two different centres regarding joint space narrowing measurement in knee osteoarthritis
Deroisy, Rita ULg; Roux, J. P.; Bruyère, Olivier ULg et al

in Osteoporosis International (2010, May), 21(Suppl.1), 233-234

Detailed reference viewed: 18 (4 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate: new data on fracture prevention and mechanisms of action.
Reginster, Jean-Yves ULg; Deroisy, Rita ULg; Neuprez, Audrey et al

in Current Osteoporosis Reports (2009), 7(3), 96-102

Osteoporosis treatments need to combine an unequivocally demonstrated reduction of fractures, at various skeletal sites, long-term safety, and a user-friendly profile that optimizes therapeutic adherence ... [more ▼]

Osteoporosis treatments need to combine an unequivocally demonstrated reduction of fractures, at various skeletal sites, long-term safety, and a user-friendly profile that optimizes therapeutic adherence. Strontium ranelate is the first compound to simultaneously decrease bone resorption and stimulate bone formation. Its anti-fracture efficacy at various skeletal sites has been established for as long as 5 years through studies of the highest methodological standards. Increases in bone mineral density observed after 1 year of treatment are predictive of the long-term fracture efficacy, suggesting for the first time in osteoporosis that bone densitometry can be used as a monitoring tool. Due to a positive risk/benefit ratio, strontium ranelate is now considered as a first-line treatment in the management of osteoporosis. [less ▲]

Detailed reference viewed: 35 (1 ULg)
Full Text
Peer Reviewed
See detailBone mineral density and health related quality of life: a 3-year follow-up study of osteoportic postmenopaul women
Bruyère, Olivier ULg; De Cock, Caroline; Deroisy, Rita ULg et al

in The Open Geritric Medicine Journal (2009), 2

Objective: The objective of this study was to evaluate the relationship between change in bone mineral density (BMD) and change in health related quality of life (HRQoL) over a 3-year eriod, in patients ... [more ▼]

Objective: The objective of this study was to evaluate the relationship between change in bone mineral density (BMD) and change in health related quality of life (HRQoL) over a 3-year eriod, in patients without incident of osteoporotic fracture. Materials and Methods: Prior to the present study, two randomized controlled trials had been carried out to assess the efficacy of a new anti-osteoporotic drug. From the placebo group of those two trials, we selected for the present study 1838 osteoporotic postmenopausal women aged over 50 years, and followed their progress for a period of 3 years. BMD was measured at the lumbar spine and the proximal femur by dual-energy X-ray absorptiometry. Each patient received calcium and vitamin D supplements. HRQoL was assessed using 2 questionnaires: the generic tool Short Form 36 items (SF-36; including mental and physical components) and the specific Quality of Life Questionnaire in Osteoporosis (QUALIOST). Result: At baseline, after adjustment for body mass index (BMI), age, number of vertebral fractures and number of peripheral fractures, multivariate regression analysis showed a significant association between the lumbar BMD and the mental component of the SF-36 (p<0.001). However, the relationship was not significant with the global score of the QUALIOST (p=0.098) and the physical component of the SF-36 (p=0.051). Multivariate regressions did not show a significant relationship between HRQoL and proximal femur BMD at baseline. After 3 years of follow-up, multivariate regression analysis showed no significant association between change in lumbar BMD and the main HRQoL items (global score of the QUALIOST, physical and mental components of the SF-36; p between 0.437 and 0.942). No significant relationships were found between change in femoral BMD and change in the global score of the QUALIOST (p=0.088) or change in the mental component of the SF-36 (p=0.222). However, a significant positive association (p=0.031) appeared between change in the physical component of the SF-36 and femoral BMD change. Conclusion: In osteoporotic postmenopausal women receiving calcium and vitamin D, few relationships were found between BMD and HRQoL. However, these results were not strong enough to indicate a real clinically interesting relationship between HRQoL and BMD. Other studies would need to be performed to verify these results. [less ▲]

Detailed reference viewed: 33 (4 ULg)
Full Text
Peer Reviewed
See detailAssociation between lumbar disc degeneration and biochemical markers of bone and cartilage remodelling
Bruyère, Olivier ULg; Collette, Julien ULg; Christiansen, F. et al

in Annals of the Rheumatic Diseases (2008, June), 67(Suppl.II), 231

Detailed reference viewed: 16 (3 ULg)
Full Text
Peer Reviewed
See detailAssociation between spinal osteoarthritis and biochemical markers of bone and cartilage remodelling
Bruyère, Olivier ULg; Collette, Julien ULg; Christiansen, C. et al

in Osteoporosis International (2008, April), 19(Suppl.1), 200

Detailed reference viewed: 16 (4 ULg)
Full Text
Peer Reviewed
See detailRole of Biochemical Markers of Bone Turnover as Prognostic Indicator of Successful Osteoporosis Therapy
Reginster, Jean-Yves ULg; Collette, Julien ULg; Neuprez, Audrey et al

in BONE (2008), 42

Most of the currently available anti-osteoporosis medications promptly and significantly influence the rate of bone turnover. Biochemical markers of bone turnover now provide a high sensitivity to change ... [more ▼]

Most of the currently available anti-osteoporosis medications promptly and significantly influence the rate of bone turnover. Biochemical markers of bone turnover now provide a high sensitivity to change, allowing the detection of these bone turnover changes within a couple of weeks. Since the anti-fracture efficacy of inhibitors of bone resorption or stimulators of bone formation appears to be largely independent of baseline bone turnover, biochemical markers do not appear to play a significant role in the selection of one particular drug, for an individual patient. However, there are consistent data showing that short-term changes in biochemical markers of bone turnover may be significant predictors of future changes in bone mineral density or fracture reduction, hence suggesting that bone turnover markers play a significant role in the monitoring of anti-osteoporosis therapy. [less ▲]

Detailed reference viewed: 61 (11 ULg)
Full Text
Peer Reviewed
See detailTotal Joint Replacement after Glucosamine Sulphate Treatment in Knee Osteoarthritis: Results of a Mean 8-Year Observation of Patients from Two Previous 3-Year, Randomised, Placebo-Controlled Trials
Bruyère, Olivier ULg; Pavelka, K.; Rovati, L. C. et al

in Osteoarthritis and Cartilage (2008), 16(2), 254-60

OBJECTIVE: To assess the incidence of Total Joint Replacement (TJR) during the long-term follow-up of patients with knee osteoarthritis (OA) formerly receiving treatment with glucosamine sulphate or ... [more ▼]

OBJECTIVE: To assess the incidence of Total Joint Replacement (TJR) during the long-term follow-up of patients with knee osteoarthritis (OA) formerly receiving treatment with glucosamine sulphate or placebo. METHODS: Knee OA patients participating in two previous randomised, placebo-controlled, double-blind, 3-year trials of glucosamine sulphate and receiving treatment for at least 12 months, were systematically contacted to participate in a long-term follow-up retrospective assessment of the incidence of total knee replacement. RESULTS: Out of 340 patients with at least 12 months of treatment, 275 (i.e., 81%) could be retrieved and interviewed for the present evaluation: 131 formerly on placebo and 144 on glucosamine sulphate. There were no differences in baseline disease characteristics between groups or with the patients lost to follow-up. The mean duration of follow-up was approximately 5 years after trial termination and treatment discontinuation, making up a total of 2178 patient-years of observation (including treatment and follow-up). Total knee replacement had occurred in over twice as many patients from the placebo group, 19/131 (14.5%), than in those formerly receiving glucosamine sulphate, 9/144 (6.3%) (P=0.024, chi-square test), with a Relative Risk that was therefore 0.43 (95% confidence interval (CI): 0.20-0.92), i.e., a 57% decrease compared with placebo. The Kaplan Meier/Log-Rank test survival analysis confirmed a significantly decreased (P=0.026) cumulative incidence of total knee replacements in patients who had received glucosamine sulphate. A pharmacoeconomic analysis in a subgroup of subjects suggested that patients formerly on glucosamine sulphate had recurred to less symptomatic medications and use of other health resources than those from the placebo group during the last year of follow-up. CONCLUSIONS: Treatment of knee OA with glucosamine sulphate for at least 12 months and up to 3 years may prevent TJR in an average follow-up of 5 years after drug discontinuation. [less ▲]

Detailed reference viewed: 147 (6 ULg)
Full Text
Peer Reviewed
See detailTotal joint replacement after glucosamine sulfate treatment of knee osteoarthritis: results from a 8-year prospective cohort
Bruyère, Olivier ULg; Pavelka, K.; Rovati, Lucio C et al

in Osteoporosis International (2007, March), 18(Suppl.1), 81

Detailed reference viewed: 14 (0 ULg)